Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

John W. Eikelboom, Stuart J. Connolly, Jackie Bosch, Gilles R. Dagenais, Robert G. Hart, Olga Shestakovska, Rafael Diaz, Marco Alings, Eva M. Lonn, Sonia S. Anand, Petr Widimsky, Masatsugu Hori, Alvaro Avezum, Leopoldo S. Piegas, Kelley R.H. Branch, Jeffrey Probstfield, Deepak L. Bhatt, Jun Zhu, Yan Liang, Aldo P. Maggioni & 30 others Patricio Lopez-Jaramillo, Martin O’Donnell, Ajay Kakkar, Keith A.A. Fox, Alexander N. Parkhomenko, Georg Ertl, Stefan Störk, Matyas Keltai, Lars Ryden, Nana Pogosova, Antonio L. Dans, Fernando Lanas, Patrick J. Commerford, Christian Torp-Pedersen, Tomek J. Guzik, Peter B. Verhamme, Dragos Vinereanu, Jae-Hyung Kim, Andrew M. Tonkin, Basil S. Lewis, Camilo Felix, Khalid Yusoff, P. Gabriel Steg, Kaj P. Metsarinne, Nancy Cook Bruns, Frank Misselwitz, Edmond Chen, Darryl Leong, Salim Yusuf, Joseph Selvanayagam

Research output: Chapter in Book/Report/Conference proceedingChapter

452 Citations (Scopus)

Abstract

BackgroundWe evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. MethodsIn this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. ResultsThe primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P
LanguageEnglish
Title of host publicationNew England Journal of Medicine
PagesNEJMoa1709118
DOIs
Publication statusPublished - 27 Aug 2017

Publication series

NameNew England Journal of Medicine

Cite this

Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., ... Selvanayagam, J. (2017). Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. In New England Journal of Medicine (pp. NEJMoa1709118). (New England Journal of Medicine). https://doi.org/10.1056/NEJMoa1709118
Eikelboom, John W. ; Connolly, Stuart J. ; Bosch, Jackie ; Dagenais, Gilles R. ; Hart, Robert G. ; Shestakovska, Olga ; Diaz, Rafael ; Alings, Marco ; Lonn, Eva M. ; Anand, Sonia S. ; Widimsky, Petr ; Hori, Masatsugu ; Avezum, Alvaro ; Piegas, Leopoldo S. ; Branch, Kelley R.H. ; Probstfield, Jeffrey ; Bhatt, Deepak L. ; Zhu, Jun ; Liang, Yan ; Maggioni, Aldo P. ; Lopez-Jaramillo, Patricio ; O’Donnell, Martin ; Kakkar, Ajay ; Fox, Keith A.A. ; Parkhomenko, Alexander N. ; Ertl, Georg ; Störk, Stefan ; Keltai, Matyas ; Ryden, Lars ; Pogosova, Nana ; Dans, Antonio L. ; Lanas, Fernando ; Commerford, Patrick J. ; Torp-Pedersen, Christian ; Guzik, Tomek J. ; Verhamme, Peter B. ; Vinereanu, Dragos ; Kim, Jae-Hyung ; Tonkin, Andrew M. ; Lewis, Basil S. ; Felix, Camilo ; Yusoff, Khalid ; Steg, P. Gabriel ; Metsarinne, Kaj P. ; Cook Bruns, Nancy ; Misselwitz, Frank ; Chen, Edmond ; Leong, Darryl ; Yusuf, Salim ; Selvanayagam, Joseph. / Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine. 2017. pp. NEJMoa1709118 (New England Journal of Medicine).
@inbook{3a756232183d47698894286bf480c7c8,
title = "Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease",
abstract = "BackgroundWe evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. MethodsIn this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. ResultsThe primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1{\%}] vs. 496 patients [5.4{\%}]; hazard ratio, 0.76; 95{\%} confidence interval [CI], 0.66 to 0.86; P",
author = "Eikelboom, {John W.} and Connolly, {Stuart J.} and Jackie Bosch and Dagenais, {Gilles R.} and Hart, {Robert G.} and Olga Shestakovska and Rafael Diaz and Marco Alings and Lonn, {Eva M.} and Anand, {Sonia S.} and Petr Widimsky and Masatsugu Hori and Alvaro Avezum and Piegas, {Leopoldo S.} and Branch, {Kelley R.H.} and Jeffrey Probstfield and Bhatt, {Deepak L.} and Jun Zhu and Yan Liang and Maggioni, {Aldo P.} and Patricio Lopez-Jaramillo and Martin O’Donnell and Ajay Kakkar and Fox, {Keith A.A.} and Parkhomenko, {Alexander N.} and Georg Ertl and Stefan St{\"o}rk and Matyas Keltai and Lars Ryden and Nana Pogosova and Dans, {Antonio L.} and Fernando Lanas and Commerford, {Patrick J.} and Christian Torp-Pedersen and Guzik, {Tomek J.} and Verhamme, {Peter B.} and Dragos Vinereanu and Jae-Hyung Kim and Tonkin, {Andrew M.} and Lewis, {Basil S.} and Camilo Felix and Khalid Yusoff and Steg, {P. Gabriel} and Metsarinne, {Kaj P.} and {Cook Bruns}, Nancy and Frank Misselwitz and Edmond Chen and Darryl Leong and Salim Yusuf and Joseph Selvanayagam",
year = "2017",
month = "8",
day = "27",
doi = "10.1056/NEJMoa1709118",
language = "English",
isbn = "8457864890",
series = "New England Journal of Medicine",
pages = "NEJMoa1709118",
booktitle = "New England Journal of Medicine",

}

Eikelboom, JW, Connolly, SJ, Bosch, J, Dagenais, GR, Hart, RG, Shestakovska, O, Diaz, R, Alings, M, Lonn, EM, Anand, SS, Widimsky, P, Hori, M, Avezum, A, Piegas, LS, Branch, KRH, Probstfield, J, Bhatt, DL, Zhu, J, Liang, Y, Maggioni, AP, Lopez-Jaramillo, P, O’Donnell, M, Kakkar, A, Fox, KAA, Parkhomenko, AN, Ertl, G, Störk, S, Keltai, M, Ryden, L, Pogosova, N, Dans, AL, Lanas, F, Commerford, PJ, Torp-Pedersen, C, Guzik, TJ, Verhamme, PB, Vinereanu, D, Kim, J-H, Tonkin, AM, Lewis, BS, Felix, C, Yusoff, K, Steg, PG, Metsarinne, KP, Cook Bruns, N, Misselwitz, F, Chen, E, Leong, D, Yusuf, S & Selvanayagam, J 2017, Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. in New England Journal of Medicine. New England Journal of Medicine, pp. NEJMoa1709118. https://doi.org/10.1056/NEJMoa1709118

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. / Eikelboom, John W.; Connolly, Stuart J.; Bosch, Jackie; Dagenais, Gilles R.; Hart, Robert G.; Shestakovska, Olga; Diaz, Rafael; Alings, Marco; Lonn, Eva M.; Anand, Sonia S.; Widimsky, Petr; Hori, Masatsugu; Avezum, Alvaro; Piegas, Leopoldo S.; Branch, Kelley R.H.; Probstfield, Jeffrey; Bhatt, Deepak L.; Zhu, Jun; Liang, Yan; Maggioni, Aldo P.; Lopez-Jaramillo, Patricio; O’Donnell, Martin; Kakkar, Ajay; Fox, Keith A.A.; Parkhomenko, Alexander N.; Ertl, Georg; Störk, Stefan; Keltai, Matyas; Ryden, Lars; Pogosova, Nana; Dans, Antonio L.; Lanas, Fernando; Commerford, Patrick J.; Torp-Pedersen, Christian; Guzik, Tomek J.; Verhamme, Peter B.; Vinereanu, Dragos; Kim, Jae-Hyung; Tonkin, Andrew M.; Lewis, Basil S.; Felix, Camilo; Yusoff, Khalid; Steg, P. Gabriel; Metsarinne, Kaj P.; Cook Bruns, Nancy; Misselwitz, Frank; Chen, Edmond; Leong, Darryl; Yusuf, Salim; Selvanayagam, Joseph.

New England Journal of Medicine. 2017. p. NEJMoa1709118 (New England Journal of Medicine).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

AU - Eikelboom, John W.

AU - Connolly, Stuart J.

AU - Bosch, Jackie

AU - Dagenais, Gilles R.

AU - Hart, Robert G.

AU - Shestakovska, Olga

AU - Diaz, Rafael

AU - Alings, Marco

AU - Lonn, Eva M.

AU - Anand, Sonia S.

AU - Widimsky, Petr

AU - Hori, Masatsugu

AU - Avezum, Alvaro

AU - Piegas, Leopoldo S.

AU - Branch, Kelley R.H.

AU - Probstfield, Jeffrey

AU - Bhatt, Deepak L.

AU - Zhu, Jun

AU - Liang, Yan

AU - Maggioni, Aldo P.

AU - Lopez-Jaramillo, Patricio

AU - O’Donnell, Martin

AU - Kakkar, Ajay

AU - Fox, Keith A.A.

AU - Parkhomenko, Alexander N.

AU - Ertl, Georg

AU - Störk, Stefan

AU - Keltai, Matyas

AU - Ryden, Lars

AU - Pogosova, Nana

AU - Dans, Antonio L.

AU - Lanas, Fernando

AU - Commerford, Patrick J.

AU - Torp-Pedersen, Christian

AU - Guzik, Tomek J.

AU - Verhamme, Peter B.

AU - Vinereanu, Dragos

AU - Kim, Jae-Hyung

AU - Tonkin, Andrew M.

AU - Lewis, Basil S.

AU - Felix, Camilo

AU - Yusoff, Khalid

AU - Steg, P. Gabriel

AU - Metsarinne, Kaj P.

AU - Cook Bruns, Nancy

AU - Misselwitz, Frank

AU - Chen, Edmond

AU - Leong, Darryl

AU - Yusuf, Salim

AU - Selvanayagam, Joseph

PY - 2017/8/27

Y1 - 2017/8/27

N2 - BackgroundWe evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. MethodsIn this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. ResultsThe primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P

AB - BackgroundWe evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. MethodsIn this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. ResultsThe primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P

U2 - 10.1056/NEJMoa1709118

DO - 10.1056/NEJMoa1709118

M3 - Chapter

SN - 8457864890

T3 - New England Journal of Medicine

SP - NEJMoa1709118

BT - New England Journal of Medicine

ER -

Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. In New England Journal of Medicine. 2017. p. NEJMoa1709118. (New England Journal of Medicine). https://doi.org/10.1056/NEJMoa1709118